FDA Grants Orphan & Rare Pediatric Status to NEU-001 for Hirschsprung Disease Neurenati Therapeutics Inc., a biotechnology company specializing in rare pediatric diseases, has announced a significant regulatory milestone. The U.S. Food and Drug Administration (FDA) has granted both Orphan…
Amylyx Reports Q4 and Full-Year 2024 Financial Results Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) recently released its financial results for the fourth quarter and full year ending December 31, 2024, showcasing significant advancements in its research and…
TEVIMBRA Gains U.S. Approval for First-Line Esophageal Cancer Treatment with Chemotherapy BeiGene, Ltd. a global oncology company that has announced its intent to change its name to BeOne Medicines Ltd., recently revealed that the U.S. Food and Drug Administration (FDA)…
FairJourney Biologics Acquires Charles River’s South San Francisco Site FairJourney Biologics S.A., a global leader in antibody discovery and optimization, has announced the successful acquisition of the South San Francisco site from Charles River Laboratories International, Inc. This strategic acquisition…
Surescripts 2024 Annual Impact Report Highlights Surge in Health Intelligence Sharing, Enhancing Care Quality & Access Surescripts, the nation’s leading health information network, has released its highly anticipated 2024 Annual Impact Report, underscoring the transformative advancements in health intelligence sharing.…
Incyte (Nasdaq: INCY) has announced its participation in the 2025 American Academy of Dermatology (AAD) Annual Meeting, scheduled for March 7–11, 2025, in Orlando, where the company will present multiple abstracts showcasing new data from its dermatology portfolio. The event…
Sarepta Therapeutics Opens Applications for 8th Annual Route 79 Duchenne Scholarship Program Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in precision genetic medicine for rare diseases, has officially opened applications for the 2025-2026 academic year of Route 79, The Duchenne…
BridgeBio Oncology and Helix Acquisition Announce Merger to Advance RAS & PI3Kα Therapies BridgeBio Oncology Therapeutics (BBOT), a clinical-stage biopharmaceutical company focused on developing next-generation small molecule therapies targeting RAS and PI3Kα malignancies, has announced a definitive business combination agreement…
Predictmedix AI Unveils Advanced AI Health Stations for US Market Expansion Predictmedix AI Expands into US Market with Launch of Advanced AI Health Stations Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP) (“Predictmedix” or the “Company”), a pioneering provider…
SINOVAC Announces New Board Following Privy Council Judgment and Outlines Next Steps Sinovac Biotech Ltd. (NASDAQ:SVA) (“SINOVAC” or the “Company”), a leading biopharmaceutical company in China, has announced significant developments following a ruling from the Privy Council. On February 8,…
Genethon Advances Gene Therapy Innovations on Rare Disease Day 2025 Genethon, a pioneering gene therapy research organization founded by the AFM-Telethon, marks Rare Disease Day by showcasing groundbreaking technological advancements that promise to usher in the next generation of gene…
Glaukos Receives FDA Acceptance for Epioxa™ NDA Submission Glaukos Corporation (NYSE: GKOS), a leading ophthalmic pharmaceutical and medical technology company specializing in innovative therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, has announced a significant regulatory milestone.…
